An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which ...
Jun 28, 2012
0
0
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers ...
Dec 11, 2017
0
0
(Medical Xpress) -- An indication of whether a mother will develop pre-eclampsia, the most common and severe pregnancy-related disease, has been identified by a University of Sydney study.
May 9, 2012
0
0
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
Bouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukemia, new research has shown.
May 21, 2024
0
3
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...
Jul 5, 2012
0
0
Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant. The ...
Mar 14, 2014
0
0
At the beginning of the COVID-19 pandemic, a group of Brazilian researchers showed why SARS-CoV-2 infection tends to be more severe in diabetic patients. Now, the same team based at the Institute of Biology of the State University ...
Jul 2, 2024
0
2
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according ...
May 31, 2014
0
0
Chronic lymphocytic leukemia (CLL) patients who stopped taking the kinase inhibitors (KIs), ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy, according to a large multi-center ...
Dec 7, 2015
0
0
